Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2018 - 2026)

Mirum Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $187.6 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 61.83% year-over-year to $187.6 million in Q1 2026; TTM through Mar 2026 was $187.6 million, a 61.83% increase from a year earlier, with the FY2025 full-year figure at $196.2 million, up 75.27% from the prior year.
• Accumulated Expenses slipped to $187.6 million in Q1 2026 per MIRM's latest filing, from $196.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $196.2 million in Q4 2025 and bottomed at $6.8 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $89.6 million (2024), against an average of $87.3 million.
• Biggest YoY gain for Accumulated Expenses was 784.6% in 2022; the steepest drop was 67.16% in 2022.
• Year by year, Accumulated Expenses stood at $54.0 million in 2022, then surged by 45.4% to $78.5 million in 2023, then surged by 42.51% to $111.9 million in 2024, then soared by 75.27% to $196.2 million in 2025, then slipped by 4.36% to $187.6 million in 2026.
• Per Business Quant, the three latest MIRM Accumulated Expenses figures stand at $187.6 million (Q1 2026), $196.2 million (Q4 2025), and $148.2 million (Q3 2025).